The m6A modification catalyzed by Mettl3 has been proven to control specific target mRNAs translation efficiency and stability, which plays a key role in promoting progression of various cancers including lung cancer, endometrial cancer, leukemia, and colorectal cancer (Barbieri et al., 2017; Choe et al., 2018; Liu et al., 2018; Li et al., 2019). The gene discussed is METTL3; the disease is endometrial cancer.